ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo

Molecular Therapy

Volumn 22, Issue 10, 2014, Pages 1753-1767

  Spencer, Brian ^a   Emadi, Sharareh ^b   Desplats, Paula ^c   Eleuteri, Simona ^c   Michael, Sarah ^c   Kosberg, Kori ^c   Shen, Jay ^c   Rockenstein, Edward ^c   Patrick, Christina ^c   Adame, Anthony ^c   Gonzalez, Tania ^c   Sierks, Michael ^b   Masliah, Eliezer ^c,d  

^a NeuroTransit   (United States)

^b Arizona State University   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN B; ESCRT PROTEIN; LENTIVIRUS VECTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; NEURON SPECIFIC NUCLEAR PROTEIN; OLIGOMER; PROTEIN AGGREGATE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CHMP2B PROTEIN, MOUSE; NERVE PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG PENETRATION; ENDOCYTOSIS; HIPPOCAMPUS; IMMUNOTHERAPY; IN VIVO STUDY; LYSOSOME; MEMORY; MOUSE; NEOCORTEX; NERVE DEGENERATION; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; RAT; SINGLE DRUG DOSE; SPATIAL LEARNING; TRANSGENIC MOUSE; ADMINISTRATION AND DOSAGE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CELL LINE; CHEMISTRY; GENE ORDER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GLIA; IMMUNOLOGY; LENTIVIRINAE; METABOLISM; NERVE CELL; PATHOLOGY; PROTEIN MOTIF; PROTEIN TRANSPORT;

ALPHA-SYNUCLEIN; AMINO ACID MOTIFS; ANIMALS; APOLIPOPROTEINS B; AUTOPHAGY; BEHAVIOR, ANIMAL; BRAIN; CELL LINE; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; GENE ORDER; GENETIC VECTORS; LENTIVIRUS; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROGLIA; NEURONS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEOLYSIS; RATS; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC;

EID: 84926209020     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.129     Document Type: Article

References (50)

1. Iwai, A, Masliah, E, Yoshimoto, M, Ge, N, Flanagan, L, de Silva, HA et al. (1995). The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475.
2. Valera, E and Masliah, E (2013). Immunotherapy for neurodegenerative diseases: focus on ?-synucleinopathies. Pharmacol Ther 138: 311-322.
3. Chandra, S, Fornai, F, Kwon, HB, Yazdani, U, Atasoy, D, Liu, X et al. (2004). Doubleknockout mice for alpha-And beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 101: 14966-14971.
4. Eller, M and Williams, DR (2011). ?-Synuclein in Parkinson disease and other neurodegenerative disorders. Clin Chem Lab Med 49: 403-408.
5. Bellucci, A, Navarria, L, Zaltieri, M, Missale, C and Spano, P (2012). ?-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res 1432: 95-113.
6. Nemani, VM, Lu, W, Berge, V, Nakamura, K, Onoa, B, Lee, MK et al. (2010). Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.
7. Desplats, P, Lee, HJ, Bae, EJ, Patrick, C, Rockenstein, E, Crews, L et al. (2009). Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alphasynuclein. Proc Natl Acad Sci USA 106: 13010-13015.
8. Rey, NL, Petit, GH, Bousset, L, Melki, R and Brundin, P (2013). Transfer of human ?-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126: 555-573.
9. Ulusoy, A, Rusconi, R, Pérez-Revuelta, BI, Musgrove, RE, Helwig, M, Winzen-Reichert, B et al. (2013). Caudo-rostral brain spreading of ?-synuclein through vagal connections. EMBO Mol Med 5: 1051-1059.
10. Mougenot, AL, Nicot, S, Bencsik, A, Morignat, E, Verchére, J, Lakhdar, L et al. (2012). Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33: 2225-2228.
11. Masliah, E, Rockenstein, E, Adame, A, Alford, M, Crews, L, Hashimoto, M et al. (2005). Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857-868.
12. Masliah, E, Rockenstein, E, Mante, M, Crews, L, Spencer, B, Adame, A et al. (2011). Passive immunization reduces behavioral and neuropathological deficits in an alphasynuclein transgenic model of Lewy body disease. PLoS One 6: e19338.
13. Spencer, B, Potkar, R, Trejo, M, Rockenstein, E, Patrick, C, Gindi, R et al. (2009). Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 29: 13578-13588.
14. Bae, EJ, Lee, HJ, Rockenstein, E, Ho, DH, Park, EB, Yang, NY et al. (2012). Antibodyaided clearance of extracellular ?-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32: 13454-13469.
15. Ahmad, ZA, Yeap, SK, Ali, AM, Ho, WY, Alitheen, NB and Hamid, M (2012). scFv antibody: principles and clinical application. Clin Dev Immunol 2012: 980250.
16. Okun, E, Mattson, MP and Arumugam, TV (2010). Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med 12: 164-178.
17. Emadi, S, Barkhordarian, H, Wang, MS, Schulz, P and Sierks, MR (2007). Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 368: 1132-1144.
18. Joshi, SN, Butler, DC and Messer, A (2012). Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs 4: 686-693.
19. Spencer, BJ and Verma, IM (2007). Targeted delivery of proteins across the bloodbrain barrier. Proc Natl Acad Sci USA 104: 7594-7599.
20. Spencer, B, Marr, RA, Gindi, R, Potkar, R, Michael, S, Adame, A et al. (2011). Peripheral delivery of a CNS targeted, metalo-protease reduces a toxicity in a mouse model of Alzheimer's disease. PLoS One 6: e16575.
21. Scotti, E, Calamai, M, Goulbourne, CN, Zhang, L, Hong, C, Lin, RR et al. (2013). IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor. Mol Cell Biol 33: 1503-1514.
22. Masliah, E, Rockenstein, E, Veinbergs, I, Mallory, M, Hashimoto, M, Takeda, A et al. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269.
23. Banks, WA, Terrell, B, Farr, SA, Robinson, SM, Nonaka, N and Morley, JE (2002). Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23: 2223-2226.
24. Spencer, B, Verma, I, Desplats, P, Morvinski, D, Rockenstein, E, Adame, A et al. (2014). A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. J Biol Chem 289: 17917-17931.
25. Boado, RJ, Lu, JZ, Hui, EK, Sumbria, RK and Pardridge, WM (2013). Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol Bioeng 110: 1456-1465.
26. Jones, NH, Clabby, ML, Dialynas, DP, Huang, HJ, Herzenberg, LA and Strominger, JL (1986). Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature 323: 346-349.
27. Schubert, D, Heinemann, S, Carlisle, W, Tarikas, H, Kimes, B, Patrick, J et al. (1974). Clonal cell lines from the rat central nervous system. Nature 249: 224-227.
28. Rockenstein, E, Mallory, M, Hashimoto, M, Song, D, Shults, CW, Lang, I et al. (2002). Differential neuropathological alterations in transgenic mice expressing alphasynuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68: 568-578.
29. Fernagut, PO, Chalon, S, Diguet, E, Guilloteau, D, Tison, F and Jaber, M (2003). Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 116: 1123-1130.
30. Price, DL, Rockenstein, E, Ubhi, K, Phung, V, MacLean-Lewis, N, Askay, D et al. (2010). Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity. PLoS One 5: e14020.
31. Martinez-Vicente, M and Vila, M (2013). Alpha-synuclein and protein degradation pathways in Parkinson's disease: a pathological feed-back loop. Exp Neurol 247: 308-313.
32. Crews, L, Spencer, B, Desplats, P, Patrick, C, Paulino, A, Rockenstein, E et al. (2010). Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 5: e9313.
33. Cuervo, AM, Stefanis, L, Fredenburg, R, Lansbury, PT and Sulzer, D (2004). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295.
34. Russell, MR, Shideler, T, Nickerson, DP, West, M and Odorizzi, G (2012). Class E compartments form in response to ESCRT dysfunction in yeast due to hyperactivity of the Vps21 Rab GTPase. J Cell Sci 125(Pt 21): 5208-5220.
35. Emadi, S, Liu, R, Yuan, B, Schulz, P, McAllister, C, Lyubchenko, Y et al. (2004). Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43: 2871-2878.
36. Zhou, C, Emadi, S, Sierks, MR and Messer, A (2004). A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 10: 1023-1031.
37. Benner, EJ, Mosley, RL, Destache, CJ, Lewis, TB, Jackson-Lewis, V, Gorantla, S et al. (2004). Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101: 9435-9440.
38. Winner, B, Jappelli, R, Maji, SK, Desplats, PA, Boyer, L, Aigner, S et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108: 4194-4199.
39. Tsigelny, IF, Crews, L, Desplats, P, Shaked, GM, Sharikov, Y, Mizuno, H et al. (2008). Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One 3: e3135.
40. Rockenstein, E, Nuber, S, Overk, CR, Ubhi, K, Mante, M, Patrick, C et al. (2014). Accumulation of oligomer-prone ?-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 137(Pt 5): 1496-1513.
41. Marongiu, R, Spencer, B, Crews, L, Adame, A, Patrick, C, Trejo, M et al. (2009). Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J Neurochem 108: 1561-1574.
42. Bender, A, Desplats, P, Spencer, B, Rockenstein, E, Adame, A, Elstner, M et al. (2013). TOM40 mediates mitochondrial dysfunction induced by ?-synuclein accumulation in Parkinson's disease. PLoS One 8: e62277.
43. Li, JY, Englund, E, Holton, JL, Soulet, D, Hagell, P, Lees, AJ et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14: 501-503.
44. Lee, HJ, Patel, S and Lee, SJ (2005). Intravesicular localization and exocytosis of alphasynuclein and its aggregates. J Neurosci 25: 6016-6024.
45. Mollenhauer, B, Cullen, V, Kahn, I, Krastins, B, Outeiro, TF, Pepivani, I et al. (2008). Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325.
46. Hussain, MM, Strickland, DK and Bakillah, A (1999). The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 19: 141-172.
47. Lee, JA and Gao, FB (2009). Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia. J Neurosci 29: 8506-8511.
48. Lata, S, Schoehn, G, Solomons, J, Pires, R, Göttlinger, HG and Weissenhorn, W (2009). Structure and function of ESCRT-III. Biochem Soc Trans 37(Pt 1): 156-160.
49. Spencer, B, Michael, S, Shen, J, Kosberg, K, Rockenstein, E, Patrick, C et al. (2013). Lentivirus mediated delivery of neurosin promotes clearance of wild-type ?-synuclein and reduces the pathology in an ?-synuclein model of LBD. Mol Ther 21: 31-41.
50. Desplats, PA, Kass, KE, Gilmartin, T, Stanwood, GD, Woodward, EL, Head, SR et al. (2006). Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96: 743-757.